Pregabalin

Introduction Overview

Generic Name

pregabalin

Brand Name

Lyrica

Dosage Form

oral capsule, oral solution, extended-release tablet (Lyrica CR)

Drug Class

Gamma-aminobutyric acid analogs

Pharmacokinetics

Absorption:
Pregabalin is rapidly absorbed when administered orally, with peak plasma concentrations typically achieved within 1 hour post-dose under fasting conditions. The oral bioavailability of pregabalin is approximately 90% or higher and is dose-independent up to 600 mg/day, allowing predictable systemic exposure across the approved dosing range. Food intake does not affect the extent of absorption but may delay the time to peak concentration by approximately 1 hour, without clinically significant impact on efficacy or safety. Clinical studies have demonstrated that steady-state plasma concentrations are reached within 1 day of repeated twice-daily dosing, supporting its twice-daily administration schedule.

Distribution:
Pregabalin is characterized by a relatively low plasma protein binding (less than 5%), which suggests minimal interaction with highly protein-bound drugs and a predominantly free drug concentration available for therapeutic activity. Its volume of distribution is approximately 0.5 L/kg, indicative of extensive distribution into the total body water compartments but limited penetration into adipose tissue. The drug crosses the blood-brain barrier efficiently via the L-type amino acid transporter, facilitating its central nervous system actions. Furthermore, pregabalin has been shown to be detectable in cerebrospinal fluid, aligning with its efficacy for neurological indications. Distribution is not significantly affected by age, gender, or renal impairment, although plasma levels may increase in renal dysfunction due to decreased clearance.

Metabolism:
Pregabalin undergoes negligible metabolism in humans, with over 90% of the administered dose excreted unchanged in urine. It is not significantly metabolized by hepatic enzymes, including cytochrome P450 isoenzymes; therefore, pregabalin has a low potential for hepatic drug-drug interactions. Trace amounts of metabolites detected in urine do not contribute to pharmacologic activity. The absence of metabolism means that pregabalin is unlikely to be affected by hepatic impairment, but dose adjustments are necessary for renal impairment to prevent accumulation.

Elimination:
The primary route of elimination is renal excretion, with approximately 90% or more of the dose recovered unchanged in urine. The elimination half-life ranges from 6.3 to 7 hours in individuals with normal renal function. Clearance is directly proportional to creatinine clearance, necessitating dosage adjustments in patients with compromised renal function. In patients with end-stage renal disease undergoing dialysis, pregabalin is removed by hemodialysis, with approximately 50% being eliminated during a 4-hour dialysis session. The dose timing should consider dialysis schedules to maintain therapeutic levels and avoid toxicity. No significant accumulation occurs with repeated dosing in patients with normal renal function. These pharmacokinetic characteristics highlight the crucial role of renal function in pregabalin's disposition and dosing considerations.

Dosage Forms

Available Dosage Forms:
- Oral capsules available in strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.
- Oral solution available at a concentration of 20 mg/mL, allowing for flexible dose adjustments particularly in patients with dosing difficulties or renal impairment.
- Extended-release tablets (Lyrica CR) available for once-daily dosing, indicated for diabetic peripheral neuropathy and postherpetic neuralgia.

Dosages for Adults and Adolescents:
- For neuropathic pain due to diabetic peripheral neuropathy or postherpetic neuralgia, initial dosing typically starts at 50 mg three times daily (or 75 mg twice daily), with titration based on response and tolerability to a usual effective dose ranging from 150 mg to 600 mg per day.
- For fibromyalgia treatment, dosing generally commences at 75 mg twice daily, titrating up to 150–225 mg twice daily, with maximum doses not exceeding 450 mg per day.
- As adjunctive therapy for partial-onset seizures, dosing starts at 150 mg per day divided into two or three doses and may be increased to a range of 300 to 600 mg per day depending on clinical response.
- Pediatric use for seizures is approved for patients 1 month of age and older with dosage adjustments based on weight and clinical judgment.

Specific Patient Populations:
- Renal Impairment: Dose modification is mandatory; dosing frequency and amounts are reduced according to creatinine clearance levels to prevent drug accumulation and toxicity.
- Geriatric Patients: Due to age-related decline in renal function, careful dose titration and monitoring are recommended.
- Pregnancy: Pregabalin crosses the placenta; use only if the benefits outweigh the risks, with no dosage form adjustments but special clinical monitoring.
- Lactation: Pregabalin is excreted in breast milk; breastfeeding is generally not recommended during treatment.
- In patients with hepatic impairment, no dosage adjustment is required as pregabalin is not metabolized significantly by the liver.

The availability of multiple titratable dosage forms and strengths facilitates individualized therapy based on patient-specific factors, clinical indication, and tolerability profiles.

Mechanism Of Action

Pregabalin, the active ingredient in Lyrica, is a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA), yet it does not act on GABA receptors nor directly influence GABA uptake or degradation. Instead, its primary mechanism involves binding with high affinity to the alpha2-delta subunit of voltage-gated calcium channels located on presynaptic nerve terminals in the central nervous system. This binding modulates calcium influx into the neurons upon depolarization, reducing the release of several excitatory neurotransmitters, including glutamate, norepinephrine, substance P, and calcitonin gene-related peptide.

By diminishing the release of these excitatory neurotransmitters, pregabalin effectively decreases neuronal excitability and synaptic neurotransmission associated with neuropathic pain, epilepsy, and anxiety-related disorders. This leads to a reduction in neuropathic pain signaling and stabilization of nerve activity that contributes to seizure control. The exact modulation of neuronal circuits entails decreased hyperexcitability of damaged or dysfunctional nerve fibers implicated in the pathophysiology of fibromyalgia, diabetic neuropathy, and postherpetic neuralgia.

At a cellular level, pregabalin's binding to the alpha2-delta subunit inhibits abnormal ectopic neuronal firing and synaptic plasticity changes that exacerbate chronic pain states and seizure propagation. Its effects are dose-dependent and reversible upon cessation, with a rapid onset of action in reducing abnormal neuronal discharges. Comparative with other anticonvulsants like gabapentin, pregabalin exhibits higher binding affinity and bioavailability, leading to more predictable pharmacodynamics.

Clinical implications of this mechanism include the drug’s efficacy across multiple indications involving neuropathic pain and seizure disorders, with a relatively favorable side effect profile due to its selective binding and lack of direct GABAergic activity. Ongoing research continues to explore additional pathways influenced by pregabalin, including potential impacts on neuroinflammation and central sensitization processes.

Pharmacological Actions

Binding to the alpha2-delta subunit of voltage-gated calcium channels reduces calcium influx into presynaptic neurons.
Inhibition of excitatory neurotransmitter release such as glutamate, norepinephrine, and substance P.
Reduction of neuronal hyperexcitability in central and peripheral nervous system pathways.
Attenuation of synaptic transmission related to neuropathic pain and seizure activity.
Modulation of central sensitization mechanisms involved in chronic pain syndromes.
Stabilization of neuronal membranes leading to decreased seizure frequency in epilepsy.
Reduction of neurotransmitter release implicated in anxiety and fibromyalgia symptoms.
Lack of direct activity on GABA receptors minimizing sedation and cognitive side effects.
High oral bioavailability and predictable pharmacokinetics facilitating dose titration.
Minimal metabolism and limited drug-drug interactions due to renal clearance.
Efficacy in reducing ectopic firing from damaged peripheral nerves.
Potential influence on neuroinflammatory mediators being explored.
Improvement in sleep quality related to pain reduction in fibromyalgia patients.
Dose-dependent analgesic and anticonvulsant effects demonstrated in clinical trials.
Produces neuroprotective effects by limiting excitotoxic neuronal activity.

Therapeutic Or Clinical Uses

Adjunctive therapy for partial-onset seizures in adult and pediatric patients (≥1 month old).
Management of neuropathic pain associated with diabetic peripheral neuropathy in adults.
Treatment of postherpetic neuralgia (nerve pain following shingles) in adults.
Relief of fibromyalgia symptoms including widespread musculoskeletal pain and tenderness.
Management of neuropathic pain related to spinal cord injury.
Off-label use for generalized anxiety disorder in some clinical settings.
Reduction of neuropathic pain severity in chronic peripheral nerve injuries.
As part of multimodal pain management protocols in select chronic pain syndromes.
Potential adjunct for treatment-resistant focal epilepsy based on emerging evidence.
Therapeutic option for patients intolerant to first-line neuropathic pain agents.
Used in patients requiring rapid titration due to its favorable pharmacokinetic profile.
Treatment consideration in patients with comorbid diabetes and neuropathic pain.
Selected use in palliative care for neuropathic symptom management.
Considered in therapy for neuropathic components of complex regional pain syndrome.
Investigation ongoing for use in some chronic anxiety-related neurological disorders.

Side Or Adverse Effects

Dizziness and somnolence are the most commonly reported adverse effects, often dose-dependent.
Peripheral edema and swelling of hands and feet due to fluid retention.
Weight gain associated with increased appetite and fluid accumulation.
Blurred vision or diplopia reported, generally reversible upon dose adjustment.
Dry mouth occurring in a significant proportion of patients.
Cognitive effects including trouble concentrating or attention deficits.
Unusual mood or behavioral changes such as irritability, agitation, or euphoria.
Increased risk of suicidal ideation and behavior; requires monitoring during treatment.
Severe allergic reactions including angioedema, rash, hives, and anaphylaxis.
Respiratory depression and life-threatening breathing problems particularly in patients with COPD or elderly.
Withdrawal symptoms upon abrupt discontinuation including increased seizure frequency and insomnia.
Muscle pain, tenderness, or weakness possibly indicating rhabdomyolysis.
Confusion, extreme drowsiness, or weakness necessitating medical evaluation.
Skin sores and delayed wound healing reported in diabetic patients.
Rare cases of thrombocytopenia and bleeding disorders have been documented.

Precautions

Caution advised in patients with pre-existing renal impairment; dosage adjustment necessary.
Monitor for mood changes, depression, and suicidal ideation throughout therapy.
Avoid abrupt discontinuation to prevent withdrawal symptoms and seizure exacerbation.
Use cautiously in patients with congestive heart failure due to risk of fluid retention.
Avoid use in pediatric patients under 1 month old for seizures and under 18 years for neuropathic pain indications.
Do not use during breastfeeding due to excretion in human milk and unknown effects on infant.
Pregnancy risk requires careful assessment; potential for fetal harm has been observed in animal studies.
Monitor diabetic patients for skin complications and delayed wound healing.
Avoid concurrent use with CNS depressants without medical supervision due to additive sedation and respiratory depression.
Assess history of substance abuse given potential for misuse in susceptible individuals.
Use with caution in patients with chronic lung disease such as COPD.
Perform regular renal function tests to optimize dosing and reduce toxicity risk.
Educate patients on signs of allergic reactions and respiratory distress.
Avoid alcohol consumption as it may exacerbate CNS depressant effects.
Patients should be informed about possible dizziness and advised regarding activities requiring alertness.

Warnings

Lyrica can cause severe allergic reactions including angioedema requiring immediate medical attention.
Risk of suicidal thoughts and behaviors; close monitoring for changes in mood or behavior is essential.
Do not discontinue therapy suddenly; gradual tapering recommended to minimize withdrawal and seizure risk.
Respiratory depression may be life-threatening, especially in elderly patients or those with pulmonary disease.
Weight gain and peripheral edema may exacerbate heart failure or other cardiovascular conditions.
Not approved for use in pediatric patients under 18 for neuropathic pain indications.
Pregnancy registry exists for monitoring fetal exposure; risks must be balanced against therapeutic benefits.
May cause dizziness and somnolence; patients should avoid driving or operating machinery until fully aware of effects.
Concomitant use with other CNS depressants can potentiate sedation and respiratory depression.
Monitor patients with a history of substance abuse for potential misuse or dependence.
High risk of serious skin reactions requiring immediate discontinuation.
In diabetic patients, monitor for signs of infection and impaired healing of skin lesions.
Extended-release tablets must not be crushed or chewed to avoid dose dumping and toxicity.
Potential reversible decrease in male fertility observed in animal studies; counseling advised.
Pregabalin is classified as a Schedule V controlled substance due to potential abuse liability.

Contraindication

Known hypersensitivity to pregabalin or any component of the formulation.
History of angioedema or severe allergic reactions attributed to pregabalin.
Do not administer to pediatric patients under 1 month of age for seizure treatment.
Avoid use in pediatric patients under 18 years for treatment of neuropathic pain unless specifically advised.
Patients with hypersensitivity to other gamma-aminobutyric acid analogs may require caution.
Contraindicated where the risk of respiratory depression is unacceptable and cannot be monitored safely.
Not recommended in patients with severe renal impairment without appropriate dose adjustment.
Concomitant use with other specific seizure medications may require contraindication based on individual risk assessment.
Patients with active bleeding disorders or thrombocytopenia should avoid pregabalin unless benefits outweigh risks.
Contraindicated in patients with known severe pulmonary diseases without proper medical supervision.
Not to be used during breastfeeding due to risk of exposure to the infant.
Should not be used in patients with uncontrolled mood disorders without psychiatric management.
Avoid use in patients with known intolerance to lactose or excipients present in the formulation.
Contraindicated in patients unable to swallow capsules or tablets who cannot use the oral solution formulation.
Avoid in patients with history of drug or alcohol addiction unless closely supervised.

Drug Interactions

Concurrent use with opioids increases risk of respiratory depression, sedation, and death; avoid or use with extreme caution.
Additive CNS depressant effects with benzodiazepines, muscle relaxants, antipsychotics, or other sedatives may impair cognition and motor skills.
No significant interactions with cytochrome P450 metabolized drugs due to pregabalin's renal excretion and lack of metabolism.
Possible increased serum levels of pioglitazone and rosiglitazone due to reported interactions; monitor glucose control carefully.
Enhanced risk of edema and hypotension when combined with ACE inhibitors such as enalapril, lisinopril, or ramipril.
Concomitant administration with other antiepileptic drugs requires dose careful titration and monitoring of CNS adverse effects.
Minimal interaction with oral contraceptives, but clinical monitoring advised due to possible CNS side effects affecting compliance.
Alcohol potentiates CNS depressant effects leading to increased drowsiness and dizziness.
Co-administration with lithium requires monitoring due to potential augmentation of neurotoxicity.
Use with caution alongside other medications causing weight gain or fluid retention to avoid exacerbation.
Interaction with drugs that alter renal function may affect pregabalin clearance and plasma concentrations.
No major interactions reported with commonly used antihypertensives outside of ACE inhibitors.
No clinically relevant pharmacokinetic interactions observed with medications such as metformin or statins.
Caution advised when combined with muscle relaxants or anesthesia due to additive sedative effects.
Herbal supplements with sedative properties (e.g., valerian, kava) may increase pregabalin's CNS depressant effects.

Preparations Of The Drug

Immediate-release oral capsules available in multiple strengths (25 mg to 300 mg) for flexible dosing.
Oral solution formulation at 20 mg/mL concentration for patients requiring liquid dosage form.
Extended-release tablets (Lyrica CR) designed for once-daily dosing in specific neuropathic pain indications.
Packaging includes safety child-resistant bottles and calibrated dosing syringes for liquid formulation.
Available as generic pregabalin immediate-release capsules and oral solution in the United States.
Brand Lyrica and generic forms contain identical active ingredient with equivalent bioavailability.
Instructions provided to avoid crushing or chewing extended-release tablets to maintain release properties.
Available in blister packs or bottles depending on manufacturer's supply practices.
Formulations utilize excipients compatible with patients with common allergies; lactose content present in some versions.
Storage recommendation is at room temperature, protected from moisture, heat, and direct light.
Prescribing information includes guidance for dose titration, renal impairment adjustments, and patient counseling.
Manufacturers provide patient medication guides detailing side effect profiles and warnings.
Trade dress and tablet markings vary by manufacturer but are standardized to prevent medication errors.
Supplemental formulations occasionally include supporting materials such as patient information leaflets and adherence aids.
Formulations comply with regulatory standards for controlled substances given pregabalin’s Schedule V classification.